Hereditary breast carcinoma syndromes

Cancer

Volumn 80, Issue 3 SUPPL., 1997, Pages 537-542

  Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

BRCA1; BRCA2; Breast carcinoma; Genetics; Ovarian carcinoma

Indexed keywords

BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; DISEASE ASSOCIATION; GENE MUTATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; ORAL CONTRACEPTION; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030754147     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19970801)80:3+<537::aid-cncr3>3.0.co;2-6     Document Type: Conference Paper

References (44)

1. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995;56:65-71.
2. Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N, et al. Localisation of a breast cancer susceptibility gene (BRCA2) to chromosome 13q by genetic linkage analysis. Science 1994;265:2088-91.
3. Tonin P, Ghadirian P, Phelan C, Lenoir GM, Lynch HT, Letendre F, et al. Case report: a large multisite cancer family is linked to BRCA2. J Med Genet 1995;32:982-4.
4. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.
5. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCA2 6174 delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-90.
6. Tonin P, Weber B, Offit K, Couch F, Rebbeck T, Neuhausen S, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;11:1179-83.
7. Easton DF, Ford D, Peto J. Inherited susceptibility to breast cancer. Cancer Surv 1993;18:1-17.
8. Struewing JP, Abelovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of BRCA1 185 delAG mutations is approximately 1% in Ashkenazi Jewish individuals. Nat Genet 1995;11:189-200.
9. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, et al. An evaluation of genetic heterogeneity in 145 breast- ovarian cancer families. Am J Hum Genet 1995;56:254-64.
10. Narod SA, Ford D, Devilee P, Barkardottir RB, Eyfjord J, Lenoir G, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 1995b;57:958-60.
11. Serova O, Montagna M, Torchard D, Narod SA, Tonin P, Sylla B, et al. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer familles. Am J Hum Genet 1996;58:42-51.
12. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, et al. Mutation analysis of the BRCA2 gene in 49 site- specific breast cancer families. Nat Genet 1996;13:120-2.
13. Rebbeck TR, Couch FJ, Kant J, Calzone K, DeShano M, Peng Y, et al. Genetic heterogeneity in breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 1996;59:547-53.
14. Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, et al. Mutations in BRCA1 and BRCA2 in breast cancer families: is there a third gene? Am J Hum Genet 1997;60:486-95.
15. Friedman E, Gak E, Theodor L, Bruchim R, Hirsch G, Krigligokova A, et al. BRCA1 185 del AG mutation in ovarian cancer patients and Iraqi Jews in Israel. Am J Hum Genet 1996;59:A67.
16. Lloyd KM, Dennis M. Cowden's disease: a possible new symptom complex with multiple system involvement. Ann Intern Med 1963;58:136-42.
17. Nelen MR, Padberg GW, Peelers EAG, Lin AY, van den Helm B, Frants RR, et al. Localisation of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114-6.
18. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Li FP, et al. Follow-up study of twenty-four families with the Li-Fraumeni syndrome. Cancer Res 1991;51:6094-7.
19. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DN. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990;250:1233-8.
20. Sidransky D, Tokino T, Helzsouer K, Zehnbauer B, Rausch G, Shelton B. Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52:2984-6.
21. Borresen AL, Anderson TI, Garber J, Barbier-Piraux N, Thorlacius S, et al. Screening for Tp53 mutations in breast cancer patients. Cancer Res 1992;52:3234-6.
22. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasis. N Engl J Med 1991;325:1831-6.
23. Pippard EC, Hall AJ, Barker DJP, Bridges BA. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res 1988;48:2929-32.
24. Vorechovsky I, Luo L, Lindblom A, Negrini M, Webster DB, Croce CM, et al. ATM mutations in cancer families. Cancer Res 1996;56:4130-3.
25. Sobol H, Birnbaum D, Eisinger F. Evidence for a third breast cancer susceptibility gene. Lancet 1994;344:1151-2.
26. Gayther SA, Warren W, Mazoyer S, Russel PA, Harrington PA, Chiano M, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype- phenotype correlation. Nat Genet 1995;11:428-33.
27. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, et al. A polymorphic stop codon in BRCA2. Nat Genet 1996;14:253-4.
28. Thorlacius S, Olafsdottier G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-9.
29. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
30. Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R, Ives E, et al. Risk modifiers in BRCA1 carriers. Int J Cancer 1995;64:394-8.
31. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Lynch HT, Lenoir GM, et al. The risk of ovarian cancer in BRCA1 carriers is modified by the HRAS1 locus. Nat Genet 1996;12:309-11.
32. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth and a family history of breast cancer. Am J Epidemiol 1988;128:467-77.
33. Skolnick MH, Cannon-Albright L, Goldgar DA, et al. Inheritance of proliferative breast disease in breast cancer kindreds. Science 1990;250:1715-20.
34. Sun C, Lenoir GM, Lynch H, Narod S. In situ breast cancer and BRCA1. Lancet 1996;348:408.
35. Jacquemier J, Eisinger F, Guinebretiere J-M, Stoppa-Lyonnet D, Sobol H. Intraductal component and BRCA1-associated breast cancer. Lancet 1996;348:1098.
36. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6.
37. Porter DE, Cohen BB, Wallace MR, Smyth E, Dixom M, Steel CM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994;81:1512-5.
38. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer, pathobiology, prognosis, BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
39. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study. 1. Breast cancer detection and death rates among women aged 40-49 years. Can Med Assoc J 1992;147:1459-76.
40. Early Breast Cancer Trialists Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992;339:1-5, 71-8.
41. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 111 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
42. Parazinni F, Fraanchesi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol 1991;43:9-23.
43. Stampfer MJ, Colditz GA, Willet WC, Manson JE, Rosner B, Speizer FE. Post-menopausal estrogen therapy and cardiovascular disease. Ten year follow-up from the Nurses Health Study. N Engl J Med 1989;321:293-7.
44. Steinberg K, Thacker S, Smith S, Stroup DF, Zack MM, Flanders WD. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.